Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AmDerma Pharmaceuticals, LLC

Latest From AmDerma Pharmaceuticals, LLC

Deals Shaping The Medical Industry, September 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device

Safeguard Jumps Into Life Science But Leaves Behind Early-Stage Risk

With two major exits and a third pending, the traditionally high-tech-heavy investor's new strategy is paying off. Safeguard's lower appetite for risk in the life sciences means focusing on companies with existing or near-term revenues, cash flow, and net worth being built up, rather than dependence on a regulatory or clinical milestone as an inflection point. The firm also boasts an ability to bolster the management and operational capabilities of its young companies.

United States Business Strategies

Transdermal Drug Delivery: More Than Skin Deep

Start-ups continue to seize opportunities for delivering new and existing drugs transdermally. They are also poised to capitalize on next-generation technologies for delivering macromolecules through the skin. In this issue, we profile AllTranz, Ocelus, Quinnova Pharmaceuticals and Syntropharma.

BioPharmaceutical

Quinnova Pharmaceuticals Inc.

Quinnova Pharmaceuticals Inc.'s Proderm Technology delivery system is a water-lipid-based formulation designed to apply active ingredients to the skin for the treatment of inflammatory skin diseases. Several Proderm products are already on the market. The start-up's TwinDerm technology - a two-step, single-unit topical system that allows delivery of two products in sequence from a single pouch - is designed to make treatment simpler and more convenient, therefore improving patient compliance.

BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register